Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area - PubMed (original) (raw)

. 2020 May 26;323(20):2052-2059.

doi: 10.1001/jama.2020.6775.

Jamie S Hirsch 1 2 3, Mangala Narasimhan 2, James M Crawford 2, Thomas McGinn 1 2, Karina W Davidson 1 2; the Northwell COVID-19 Research Consortium; Douglas P Barnaby 1 2, Lance B Becker 2, John D Chelico 1 2, Stuart L Cohen 1 2, Jennifer Cookingham 1, Kevin Coppa 3, Michael A Diefenbach 1, Andrew J Dominello 1, Joan Duer-Hefele 1, Louise Falzon 1, Jordan Gitlin 2, Negin Hajizadeh 1 2, Tiffany G Harvin 1, David A Hirschwerk 2, Eun Ji Kim 1 2, Zachary M Kozel 2, Lyndonna M Marrast 1 2, Jazmin N Mogavero 1, Gabrielle A Osorio 1, Michael Qiu 3, Theodoros P Zanos 4

Affiliations

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Safiya Richardson et al. JAMA. 2020.

Erratum in

Abstract

Importance: There is limited information describing the presenting characteristics and outcomes of US patients requiring hospitalization for coronavirus disease 2019 (COVID-19).

Objective: To describe the clinical characteristics and outcomes of patients with COVID-19 hospitalized in a US health care system.

Design, setting, and participants: Case series of patients with COVID-19 admitted to 12 hospitals in New York City, Long Island, and Westchester County, New York, within the Northwell Health system. The study included all sequentially hospitalized patients between March 1, 2020, and April 4, 2020, inclusive of these dates.

Exposures: Confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by positive result on polymerase chain reaction testing of a nasopharyngeal sample among patients requiring admission.

Main outcomes and measures: Clinical outcomes during hospitalization, such as invasive mechanical ventilation, kidney replacement therapy, and death. Demographics, baseline comorbidities, presenting vital signs, and test results were also collected.

Results: A total of 5700 patients were included (median age, 63 years [interquartile range {IQR}, 52-75; range, 0-107 years]; 39.7% female). The most common comorbidities were hypertension (3026; 56.6%), obesity (1737; 41.7%), and diabetes (1808; 33.8%). At triage, 30.7% of patients were febrile, 17.3% had a respiratory rate greater than 24 breaths/min, and 27.8% received supplemental oxygen. The rate of respiratory virus co-infection was 2.1%. Outcomes were assessed for 2634 patients who were discharged or had died at the study end point. During hospitalization, 373 patients (14.2%) (median age, 68 years [IQR, 56-78]; 33.5% female) were treated in the intensive care unit care, 320 (12.2%) received invasive mechanical ventilation, 81 (3.2%) were treated with kidney replacement therapy, and 553 (21%) died. As of April 4, 2020, for patients requiring mechanical ventilation (n = 1151, 20.2%), 38 (3.3%) were discharged alive, 282 (24.5%) died, and 831 (72.2%) remained in hospital. The median postdischarge follow-up time was 4.4 days (IQR, 2.2-9.3). A total of 45 patients (2.2%) were readmitted during the study period. The median time to readmission was 3 days (IQR, 1.0-4.5) for readmitted patients. Among the 3066 patients who remained hospitalized at the final study follow-up date (median age, 65 years [IQR, 54-75]), the median follow-up at time of censoring was 4.5 days (IQR, 2.4-8.1).

Conclusions and relevance: This case series provides characteristics and early outcomes of sequentially hospitalized patients with confirmed COVID-19 in the New York City area.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Crawford reported receiving grants from Regeneron outside the submitted work. Dr Becker reported serving on the scientific advisory board for Nihon Kohden and receiving grants from the National Institutes of Health, United Therapeutics, Philips, Zoll, and Patient-Centered Outcomes Research Institute outside the submitted work. Dr Cohen reported receiving personal fees from Infervision outside the submitted work. No other disclosures were reported.

Comment in

Similar articles

Cited by

References

    1. Holshue ML, DeBolt C, Lindquist S, et al. ; Washington State 2019-nCoV Case Investigation Team . First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382(10):929-936. doi:10.1056/NEJMoa2001191 - DOI - PMC - PubMed
    1. The Center for Systems Science and Engineering (CSSE) at Johns Hopkins University Coronavirus COVID-19 global cases. Accessed March 30, 2020. https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594...
    1. Centers for Disease Control and Prevention Coronavirus disease 2019 (COVID-19): cases in US. Accessed March 25, 2020. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html
    1. Zhou F, Yu T, Du R, et al. . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3 - DOI - PMC - PubMed
    1. United Nations Department of Economic and Social Affairs Population Dynamics World population prospects 2019. Accessed April 6, 2020. https://population.un.org/wpp/Graphs/DemographicProfiles/Pyramid/840

Publication types

MeSH terms

LinkOut - more resources